Atherosclerosis
Volume 170, Issue 1 , Pages 105-113 , September 2003

A novel LCAT mutation (Phe382→Val) in a kindred with familial LCAT deficiency and defective apolipoprotein B-100

  • M.Nazeem Nanjee

      Affiliations

    • Cardiovascular Biochemistry Unit, St. Bartholomew's and the Royal London School of Medicine and Dentistry, Queen Mary, University of London, Charterhouse Square, London EC1M 6BQ, UK
    • Corresponding Author InformationCorresponding author. Present address: Carl T. Hayden VA Medical Center, Harrington Arthritis Research Center Campus, 300 North 18th Street, Phoenix, AZ 85006, USA. Tel.: +1-602-277-5551x6690
    • ,
  • Joseph Stocks

      Affiliations

    • Cardiovascular Biochemistry Unit, St. Bartholomew's and the Royal London School of Medicine and Dentistry, Queen Mary, University of London, Charterhouse Square, London EC1M 6BQ, UK
    • ,
  • C.Justin Cooke

      Affiliations

    • Cardiovascular Biochemistry Unit, St. Bartholomew's and the Royal London School of Medicine and Dentistry, Queen Mary, University of London, Charterhouse Square, London EC1M 6BQ, UK
    • ,
  • Henri O.F Molhuizen

      Affiliations

    • Department of Vascular Medicine G1-112b, Academic Medical Centre at the University of Amsterdam, PO Box 22700, 1100 DE Amsterdam, Netherlands
    • ,
  • Santica Marcovina

      Affiliations

    • Northwest Lipid Research Laboratories, Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, WA 98103, USA
    • ,
  • David Crook

      Affiliations

    • Cardiovascular Biochemistry Unit, St. Bartholomew's and the Royal London School of Medicine and Dentistry, Queen Mary, University of London, Charterhouse Square, London EC1M 6BQ, UK
    • ,
  • John P Kastelein

      Affiliations

    • Department of Vascular Medicine G1-112b, Academic Medical Centre at the University of Amsterdam, PO Box 22700, 1100 DE Amsterdam, Netherlands
    • ,
  • Norman E Miller

      Affiliations

    • Cardiovascular Biochemistry Unit, St. Bartholomew's and the Royal London School of Medicine and Dentistry, Queen Mary, University of London, Charterhouse Square, London EC1M 6BQ, UK

Received 18 November 2002 ,Revised 9 May 2003 ,Accepted 27 May 2003.

References 

  1. Jonas A. Lecithin cholesterol acyltransferase. Biochim. Biophys. Acta. 2000;1529:245–256
  2. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J. Lipid Res. 1995;36:211–228
  3. Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, Kastelein J. The molecular pathology of lecithin: cholesterol acyltransferase (LCAT) deficiency syndromes. J. Lipid Res. 1997;38:191–205
  4. Miettinen HE, Gylling H, Tenhunen J, Virtamo J, Jauhiainen M, Huttunen JK, et al. Molecular genetic study of Finns with hypoalphalipoproteinemia and hyperalphalipoproteinemia: a novel Gly230Arg mutation (LCATFin) of lecithin:cholesterol acyltransferase (LCAT) accounts for 5% of cases with very low serum HDL cholesterol levels. Arterioscler. Thromb. Vasc. Biol. 1997;18:591–598
  5. Steyrer E, Durovic S, Frank S, Giessauf W, Burger A, Dieplinger H, et al. The role of lecithin: cholesterol acyltransferase for lipoprotein (a) assembly. J. Clin. Invest. 1994;94:2330–2340
  6. Myant NB. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis. 1993;104:1–18
  7. Mclean J, Wion K, Drayna D, Fielding C, Lawn R. Human lecithin-cholesterol acyltransferase gene-complete gene sequence and sites of expression. Nucleic Acids Res. 1986;14:9397–9406
  8. Stocks J, Cooke CJ, Miller NE. A common lecithin:cholesterol acyltransferase gene variant (ser208→thr). Atherosclerosis. 2000;149:219–220
  9. Motti C, Funke H, Rust S, Dergunov A, Assmann G. Using mutagenic polymerase chain reaction primers to detect carriers of familial defective apolipoprotein B-100. Clin. Chem. 1991;37:1762–1766
  10. Hixon J, Vernier D. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hha-I. J. Lipid Res. 1990;31:545–548
  11. Nanjee MN, Miller NE. Sequential microenzymatic assay of cholesterol, triglycerides, and phospholipids in a single aliquot. Clin. Chem. 1996;42:915–926
  12. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin. Chem. 1972;18:499–502
  13. Nanjee MN, Doran JE, Lerch PG, Miller NE. Acute effects of intravenous infusion of apoA1/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler. Thromb. Vasc. Biol. 1999;19:979–989
  14. Kobori K, Saito K, Ito S, Kotani K, Manabe M, Kanno T. A new enzyme-linked immunosorbent assay with two monoclonal antibodies to specific epitopes measures human lecithin-cholesterol acyltransferase. J. Lipid Res. 2002;43:325–334
  15. Albers JJ, Chen C, Lacko A. Isolation, characterisation, and assay of lecithin: cholesterol acyltransferase. Methods Enzymol. 1986;129:763–783
  16. Marcovina SM, Albers JJ, Gable B, Koschinsky ML, Gaur VP. Effect of the number of apo(a) kringle 4 domains on the immunochemical measurements of Lp(a). Clin. Chem. 1995;41:246–255
  17. Marcovina SM, Albers JJ, Wijsman E, Zhang JH, Chapman NH, Kennedy H. Differences in Lp(a) concentrations and apo(a) polymorphs between black and white Americans. J. Lipid Res. 1996;37:2569–2585
  18. Marcovina SM, Zhang JH, Gaur VP, Albers JJ. Identification of 34 apolipoprotein(a) isoforms: differential expression of apolipoprotein alleles between American blacks and whites. Biochem. Biophys. Res. Commun. 1993;191:1192–1196
  19. Neary R, Bhatnagar D, Durrington P, Ishola M, Arrol S, Mackness M. An investigation of the role of lecithin:cholesterol acyltransferase and triglyceride-rich lipoproteins in the metabolism of prebeta high density lipoproteins. Atherosclerosis. 1991;89:35–48
  20. Funke H, Von Eckardstein A, Pritchard PH, Hornby AE, Wiebusch H, Motti C, et al. Genetic and phenotypic heterogeneity in familial lecithin:cholesterol acyltransferase (LCAT) deficient-six newly identified defective alleles further contribute to the structural heterogeneity in this disease. J. Clin. Invest. 1993;91:677–683
  21. Wood D, Durrington P, McInnes G, Poulter N, Rees A, Wray R. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart. 1998;80(Suppl. 2):S1–S29
  22. Gylling H, Miettinen TA. Non-cholesterol sterols, absorption and synthesis of cholesterol and apolipoprotein A-I kinetics in a Finnish lecithin-cholesterol acyltransferase deficient family. Atherosclerosis. 1992;95:25–33
  23. Vaisman BL, Klein HG, Rouis M, Berard AM, Kindt MR, Talley GD, et al. Overexpression of human lecithin-cholesterol acyltransferase leads to hyperalphalipoproteinemia in transgenic mice. J. Biol. Chem. 1995;270:12269–12275
  24. Sakai N, Vaisman BL, Koch CA, Hoyt RF, Meyn SM, Paiz JA, et al. Lecithin:cholesterol acyltransferase (LCAT) knockout mice: a new animal model for human LCAT-deficiency. Atherosclerosis. 1997;134:372–373
  25. Guerin M, Dolphin PJ, Chapman MJ. Familial lecithin:cholesterol acyltransferase deficiency-further resolution of lipoprotein particle heterogeneity in the low-density interval. Atherosclerosis. 1993;104:195–212
  26. Peelman F, Vinaimont N, Verhee A, Vanloo B, Verschelde JL, Labeur C, et al. A proposed architecture for lecithin cholesterol acyltransferase (LCAT): Identification of the catalytic triad and molecular modeling. Protein Sci. 1998;7:587–599
  27. Peelman F, Verschelde JL, Vanloo B, Ampe C, Labeur C, Tavernier J, et al. Effects of natural mutations in lecithin:cholesterol acyltransferase on the enzyme structure and activity. J. Lipid Res. 1999;40:59–69
  28. Qu SJ, Fan HZ, Blancovaca F, Pownall HJ. In-vitro expression of natural mutants of human lecithin:cholesterol acyltransferase. J. Lipid Res. 1995;36:967–974
  29. Vanloo B, Peelman F, Deschuymere K, Taveirne J, Verhee A, Gouyette C, et al. Relationship between structure and biochemical phenotype of lecithin:cholesterol acyltransferase (LCAT) mutants causing fish-eye disease. J. Lipid Res. 2000;41:752–761
  30. Schaefer JR, Scharnagl H, Baumstark MW, Schweer H, Zech LA, Seyberth H, et al. Homozygous familial defective apolipoprotein B-100-enhanced removal of apolipoprotein E-containing VLDLs and decreased production of LDLs. Arterioscler. Thromb. Vasc. Biol. 1997;17:348–353
  31. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes: inheritance and relation to Lp(a) lipoprotein concentration in plasma. J. Clin. Invest. 1987;80:458–465

PII: S0021-9150(03)00241-7

doi: 10.1016/S0021-9150(03)00241-7

Atherosclerosis
Volume 170, Issue 1 , Pages 105-113 , September 2003

Article Tools

* Image Usage & Resolution